For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| General and administrative expenses | 5,892,684 | 28,838,537.75* | - | 4,576,524 |
| Research and development expense | 2,704,393 | 3,402,744* | - | 1,439,564 |
| Research and development expense (excluding acquired in process cost) | - | 2,179,368.75* | - | - |
| Operating expenses | 8,597,077 | 34,420,650.5 | - | 6,016,088 |
| Loss from operations | -8,597,077 | -34,420,650.5* | - | -6,016,088 |
| Finance (income) expense, net | 56,561 | - | - | - |
| Finance income | - | -545,284.5* | - | 40,004 |
| Interest (expense) | 374,712 | - | - | - |
| Represents the amount of gain loss on settlements | -127,083 | -69,713.5* | - | - |
| Represents the amount if change in fair value of debentures | - | 16,177* | - | -200,000 |
| Repayment of debentures on extinguishment | - | -6,250* | - | - |
| Total other income | -445,234 | -605,071* | - | -159,996 |
| Net loss for the year | -9,042,311 | -35,025,721.5* | - | -6,176,084 |
| Deemed dividend on warrant inducement | - | 2,959,324.5* | - | - |
| Net income (loss) available to common stockholders, basic | -9,042,311 | -37,985,046* | - | - |
| Foreign exchange gain/loss | -204,249 | -43,214* | 10,828 | - |
| Comprehensive income (loss), net of tax, attributable to parent | -9,246,560 | -38,028,260 | -2 | - |
| Basic EPS | -0.31 | -2.008 | -1.12 | -0.43 |
| Diluted EPS | -0.31 | -2.008 | -1.12 | -0.43 |
| Basic Average Shares | 29,540,833 | 18,935,543 | 18,631,668 | 14,284,261 |
| Diluted Average Shares | 29,540,833 | 18,935,543 | 18,631,668 | 14,284,261 |
Medicus Pharma Ltd. (MDCXW)
Medicus Pharma Ltd. (MDCXW)